Previous 10 | Next 10 |
2024-03-24 15:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Exploratory subgroup analysis from INNOVATE-3 finds that pegylated liposomal doxorubicin (PLD) -naïve patients randomized to receive TTFields therapy and paclitaxel had a median overall survival of 16.0 months compared to 11.7 months in PLD-naïve patients treated with paclitaxel alone ...
2024-02-22 12:15:13 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q4 2023 Earnings Call Feb 22, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q4 2023 Earnings Call Transcript
2024-02-21 11:34:50 ET More on NovoCure NovoCure: Stay Cautious Amid Positive Signs NovoCure Tumor Treating Fields accepted for FDA review Novocure reports better-than-expected preliminary Q4, FY revenue Seeking Alpha’s Quant Rating on NovoCure ...
2024-02-18 08:20:00 ET Despite a holiday-shortened week, investors have their plates full with a diverse range of earnings reports across various sectors. Tech leaders NVIDIA ( NASDAQ: NVDA ) and Palo Alto Networks ( NASDAQ: PANW ) will be in focus, alongside retail gian...
2024-01-19 17:47:40 ET Summary NovoCure's FDA application for TTF in NSCLC accepted; approval expected in H2 2024. Preliminary Q4 results show $509M annual revenue. This is a slight increase from estimates but a 5% year-on-year decline. NovoCure's valuation struggles with tepi...
2024-01-18 13:35:16 ET More on Mid-day movers & stocks. Phunware, Inc. (PHUN) Q3 2023 Earnings Call Transcript Jasper Therapeutics to effect 1-for-10 reverse stock split Phunware Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Jasper Thera...
NovoCure Limited (NASDAQ: NVCR) is one of today's top gainers. The company's shares have moved 3.24% on the day to $13.05. NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company...
2024-01-18 07:24:27 ET More on NovoCure, Zai Lab, etc. Zai Lab: Strong Growth Amidst Strategic Shifts (Rating Upgrade) NovoCure: Significant Upside Even Without A Breakthrough Zai Lab Limited (ZLAB) Q3 2023 Earnings Call Transcript Novocure reports better-tha...
Novocure (NASDAQ: NVCR) today announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of non-small cell lung cancer (NSCLC), following progression on or after plati...
News, Short Squeeze, Breakout and More Instantly...
NovoCure Limited Company Name:
NVCR Stock Symbol:
NASDAQ Market:
2024-05-03 01:00:11 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q1 2024 Earnings Call May 02, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q1 2024 Earnings Call Transcript
Use of proceeds to fund working capital needs stemming from Novocure’s anticipated launch in non-small cell lung cancer and settle, upon maturity, Novocure’s convertible notes Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 milli...
Quarterly net revenues of $139 million, up 13% year-over-year, with 3,845 active patients on therapy as of March 31, 2024 Phase 3 METIS trial in brain metastases from non-small cell lung cancer met primary endpoint and will be presented as late-breaking abstract at ASCO 2024 LUNAR...